ClinicalTrials.gg
CompletedNCT02625610Updated Jun 9, 2022Results posted

Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)

A Phase 3 interventional study of Avelumab and Oxaliplatin in Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction, sponsored by EMD Serono Research & Development Institute, Inc.. Completed at 200 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-06-09.

Sponsored by EMD Serono Research & Development Institute, Inc. (part of Merck KGaA, Darmstadt, Germany) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
499
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing avelumab in Neoplasm Metastasis — 1 open to participants now, 3 under way, none of them phase 3. avelumab · Neoplasm Metastasis.

Enrollment
2nd of 10
499 · median 46
Started
2015
the only one that year
Phase 3
Only one
of the 10
Registered
2nd of 10
by date
Lead sponsor
1 of 10
EMD Serono Research & Development Institute, Inc.

Among the 10 studies testing avelumab in Neoplasm Metastasis, this one is the 2nd largest by enrollment, is the only one that started in 2015, is the only one in phase 3, and was the 2nd registered.

Neoplasm Metastasis

4,045 studies on the registry are indexed under Neoplasm Metastasis; 888 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

1 of the 10 studies testing avelumab in Neoplasm Metastasis is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About avelumab

avelumab: first FDA approval 2017 (BAVENCIO), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 689 Neoplasm Metastasis studies recruiting now, 536 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing avelumab in Neoplasm Metastasis, or all of them as a file.
02

Study summary

The purpose of this study was to demonstrate superiority of treatment with avelumab versus continuation of first-line chemotherapy.

03

Conditions studied

  • Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction

Keywords

  • Avelumab
  • Cancer
  • Unresectable
  • Locally advanced
  • Metastatic
  • Adenocarcinoma of the stomach
  • Gastro-esophageal junction
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants greater than or equal to (>=) 18 years
  • Disease must be measurable by version 1.1 (RECIST 1.1)
  • Participants with confirmed unresectable locally advanced or adenocarcinoma of the stomach or gastro-esophageal junction (GEJ)
  • Performance Status (ECOG PS) of 0 to 1 at trial entry
  • Estimated of more than 12 weeks
  • Adequate haematological, hepatic and renal functions defined by the protocol
  • Negative blood pregnancy test at Screening for women of
  • Highly effective for both male and female participants if the risk of conception exists
  • Other protocol defined inclusion criteria could apply

Exclusion criteria

Exclusion Criteria:

  • Prior therapy with any antibody or drug targeting T-cell coregulatory proteins
  • Concurrent anticancer treatment or agents
  • Prior chemotherapy for unresectable locally advanced or adenocarcinoma of the stomach or gastro-esophageal junction (GEJ)
  • Tumor shown to be human epidermal growth factor 2 plus (+)
  • Major surgery for any reason, except diagnostic , within 4 weeks of enrolment and/or if the participant has not fully recovered from the surgery within 4 weeks of enrolment
  • Participants receiving immunosuppressive agents (such as ) for any reason should be tapered off these drugs before initiation of the study treatment (with the exception of participants with adrenal insufficiency, who may continue corticosteroids at physiologic replacement dose, equivalent to \<= 10 mg prednisone daily)
  • All participants with , except those meeting the following criteria: a. Brain metastases have been treated locally, have not been progressing at least 2 months after completion of therapy, and no steroid maintenance therapy is required, and b. No ongoing neurological symptoms that are related to the brain localization of the disease (sequelae that are a consequence of the treatment of the brain metastases are acceptable)
  • Previous malignant disease (other than gastric cancer) within the last 5 years with the exception of basal or squamous cell carcinoma of the skin or carcinoma in situ (bladder, cervical, colorectal, breast)
  • Prior organ transplantation, including stem-cell transplantation
  • Significant acute or chronic infections
  • Active disease that might deteriorate when receiving an immunostimulatory agent
  • Known severe reactions to monoclonal antibodies, any history of anaphylaxis, or uncontrolled asthma (that is, 3 or more features of partially controlled asthma)
  • Persisting toxicity related to prior therapy except alopecia
  • Neuropathy Grade > 3
  • Pregnancy or lactation
  • Known alcohol or drug abuse
  • History of uncontrolled intercurrent illness including hypertension, active infection, diabetes
  • (i.e., active) cardiovascular disease
  • All other significant diseases might impair the participant's tolerance of study treatment
  • Any psychiatric condition that would prohibit the understanding or rendering of and that would limit compliance with study requirements
  • Vaccination with live or live/attenuated viruses within 55 days of the first dose of avelumab and while on trial is prohibited except for administration of inactivated vaccines
  • Legal incapacity or limited legal capacity
  • Participants will be excluded from the Induction Phase and the Maintenance Phase if administration of their chemotherapy would be inconsistent with the current local labelling (SmPC) (e.g., in regard to , warnings/precautions or special provisions) for that chemotherapy. Investigators should check updated labelling via relevant websites at the time of entry into the Induction Phase and the Maintenance Phase
  • Other protocol defined exclusion criteria could apply
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
499 participants (actual)

Study arms

  • Experimental
    Chemotherapy + Best Supportive Care (BSC)

    In Maintenance Phase, participants continued the same regimen of oxaliplatin-fluoropyrimidine doublet chemotherapy (oxaliplatin + 5FU/LV or oxaliplatin + capecitabine) as they received during the Induction Phase until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation. Participants who were not deemed eligible to receive chemotherapy at the dose and schedule specified above received BSC alone once every 3 weeks. BSC was defined as treatment administered with the intent to maximize quality of life without a specific antineoplastic regimen and was based on Investigator's discretion.

    Drug: Oxaliplatin · Drug: 5-Fluorouracil · Drug: Leucovorin · Drug: Capecitabine · Other: Best supportive care

  • Experimental
    Avelumab

    In Maintenance phase, participants received avelumab as a 1-hour intravenous (IV) infusion at 10 milligrams per kilogram (mg/kg) once every 2-week treatment cycle until progressive disease or unacceptable toxicity or discontinuation.

    Drug: Avelumab

Interventions

  • Maintenance Phase: Intravenous (IV) infusion (10 mg/kg over 1 hour) once every 2 weeks.

    Also known as: MSB0010718C, Anti PD-L1

  • Induction Phase: Oxaliplatin was administered at a dose of 85 mg per square meter (mg/m\^2) as a continuous intravenous (IV) infusion on Day 1 along with leucovorin followed by 5-Fluorouracil every 2 weeks up to 12 weeks (or) Oxaliplatin at 130 mg/m\^2 IV on Day 1 along with capecitabine twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks up to 12 weeks. Maintenance Phase: Participants were continued the same regimen of chemotherapy as they received during the Induction Phase until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation.

  • Induction Phase: 5-Fluorouracil was administered at a dose of 2600 mg/m\^2 IV continuous infusion over 24 hours on Day 1 (or) 5-FU at 400 mg/m\^2 IV push on Day 1 and 2400 mg/m\^2 IV continuous infusion over 46-48 hours (Days 1 and 2) along with oxaliplatin and leucovorin every 2 weeks up to 12 weeks. Maintenance Phase: Participants were continued the same regimen of chemotherapy as they received during the Induction Phase until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation.

  • Induction Phase: Leucovorin was administered at a dose of 200 mg/m\^2 IV (or) Leucovorin 400 mg/m\^2 IV on Day 1 along with oxaliplatin and 5-FU every 2 weeks up to 12 weeks. Maintenance Phase: Participants were continued the same regimen of chemotherapy as they received during the Induction Phase until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation.

  • Induction Phase: Capecitabine was administered at a dose of 1000 mg/m\^2 twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks along with oxaliplatin up to 12 weeks. Maintenance Phase: Participants were continued the same regimen of chemotherapy as they received during the Induction Phase every 3 weeks until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation.

  • OtherBest supportive care

    Treatment administered with the intent to maximize Quality of Life (QoL) without a specific antineoplastic regimen. These may include for example antibiotics, analgesics, antiemetics, thoracentesis, paracentesis, blood transfusions, nutritional support (including jejunostomy), and focal external-beam radiation for control of pain, cough, dyspnea, or bleeding. Best supportive care were administered per institutional guidelines and participants were visit the clinic every 3 weeks.

  • Induction Phase: Oxaliplatin will be administered at a dose of 85 mg per square meter (mg/m\^2) as a continuous intravenous (IV) infusion on Day 1 along with leucovorin followed by 5-Fluorouracil every 2 weeks up to 12 weeks (or) Oxaliplatin at 130 mg/m\^2 IV on Day 1 along with capecitabine twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks up to 12 weeks.

  • Induction Phase: 5-Fluorouracil will be administered at a dose of 2600 mg/m\^2 IV continuous infusion over 24 hours on Day 1 (or) 5-FU at 400 mg/m\^2 IV push on Day 1 and 2400 mg/m\^2 IV continuous infusion over 46-48 hours (Days 1 and 2) along with oxaliplatin and leucovorin every 2 weeks up to 12 weeks.

  • Induction Phase: Leucovorin will be administered at a dose of 200 mg/m\^2 IV (or) Leucovorin 400 mg/m\^2 IV on Day 1 along with oxaliplatin and 5-FU every 2 weeks up to 12 weeks.

  • Induction Phase: Capecitabine will be administered at a dose of 1000 mg/m\^2 twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks along with oxaliplatin up to 12 weeks.

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Overall Survival was defined as the time from randomization to the date of death due to any cause. For participants who were still alive at the time of data analysis or who were lost to follow-up, OS time was censored at the date of last contact. OS was measured using Kaplan-Meier (KM) estimates.

    Time frame: From randomization into maintenance phase up to 1276 days

Secondary outcomes

  1. Progression Free Survival (PFS) by Independent Review Committee (IRC)

    The PFS time was defined as the time from date of randomization until date of the first documentation of progressive disease (PD) or death due to any cause (whichever occurs first). PFS was assessed as per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) as per IRC. PD was defined as at least a 20 percent (%) increase in the sum of longest diameter (SLD), taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. PFS was measured using Kaplan-Meier (KM) estimates.

    Time frame: From randomization into maintenance phase up to 1276 days

  2. Best Overall Response (BOR) by Investigator Assessment

    BOR was determined by RECIST v1.1 per Investigator assessment and defined as best-confirmed response of any of following: complete response (CR), partial response (PR), stable disease (SD) and PD recorded from date of randomization until disease progression or recurrence. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in SLD of all lesions. SD: Neither sufficient increase to qualify for PD nor sufficient shrinkage to qualify for PR. PD is defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or appearance of 1 or more new lesions. PR or CR confirmed at a subsequent tumor assessment, not sooner than 5 weeks after initial documentation or at an assessment later than the next assessment after the initial documentation of PR or CR. SD confirmed at least 6 weeks after randomization. Confirmed PD equal to progression \<=2 weeks after date of randomization.

    Time frame: From randomization into maintenance phase up to 1276 days

  3. Objective Response Rate (ORR) by Investigator Assessment

    The ORR defined as the percentage of all randomized participants with a confirmed best overall response (BOR) of partial response (PR),or complete response (CR) according to RECIST v1.1 and as per Investigator assessment. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in sum of longest diameter (SLD) of all lesions.

    Time frame: From randomization into maintenance phase up to 1276 days

  4. Change From Baseline in European Quality of Life 5-dimensions (EQ-5D-5L) Health Outcome Questionnaire Through Composite Index Score up to Safety Follow-up (Up to 152.3 Weeks)

    EQ-5D-5L is comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive overall composite health state index score, with scores ranging from -0.594 to 1. A higher score indicates better health state.

    Time frame: Baseline, Week 3/4, Week 7, Week 13, Week 19, Week 25, Week 31, Week 37, Week 43, Week 49, Week 55, Week 61, Week 67, End of Treatment ( EOT up to 148 weeks) and Safety Follow-up (Up to 152.3 Weeks)

  5. Change From Baseline in European Quality of Life 5-dimensions Health Outcome Questionnaire Through Visual Analogue Scale up to Safety Follow-up (Up to 152.3 Weeks)

    EQ-5D-5L is comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive overall score using a visual analog scale (VAS) that ranged from 0 to 100 millimeter (mm), where 0 is the worst health you can imagine and 100 is the best health you can imagine.

    Time frame: Baseline, Week 3/4, Week 7, Week 13, Week 19, Week 25, Week 31, Week 37, Week 43, Week 49, Week 55, Week 61, Week 67, End of Treatment ( EOT up to 148 weeks) and Safety Follow-up (Up to 152.3 Weeks)

  6. Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) Global Health Status Scale Score up to Safety Follow-up (Up to 152.3 Weeks)

    European Organization for the Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life (QoL) in cancer participants. It consisted of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, role, cognitive, emotional, social), and 9 symptom scales/items (Fatigue, nausea and vomiting, pain, dyspnoea, sleep disturbance, appetite loss, constipation, diarrhea, financial impact. The EORTC QLQ-C30 GHS/QoL score ranges from 0 to 100; High score indicates better GHS/QoL. Score 0 represents: very poor physical condition and QoL. Score 100 represents: excellent overall physical condition and QoL.

    Time frame: Baseline, Week 3/4, Week 7, Week 13, Week 19, Week 25, Week 31, Week 37, Week 43, Week 49, Week 55, Week 61, Week 67, End of Treatment ( EOT up to 148 weeks) and Safety Follow-up (Up to 152.3 Weeks)

  7. Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Stomach Cancer Specific (EORTC QLQ-STO22 ) Questionnaire Scores up to Safety Follow-up (Up to 152.3 Weeks)

    European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Stomach Cancer Specific (EORTC QLQ-STO22 ) supplements the EORTC QLQ-C30 to assess symptoms and treatment-related side effects commonly reported in participants. There are 22 questions which comprise 5 scales (dysphagia, pain, reflux symptom, dietary restrictions, and anxiety) and 4 single items (dry mouth, hair loss, taste, body image). Most questions use 4-point scale (1 'Not at all' to 4 'Very much'; 1 question was a yes or no answer). A linear transformation was used to standardize all scores and single-items to a scale of 0 to 100; higher score=better level of functioning or greater degree of symptoms.

    Time frame: Baseline, Week 3/4, Week 7, Week 13, Week 19, Week 25, Week 31, Week 37, Week 43, Week 49, Week 55, Week 61, Week 67, End of Treatment ( EOT up to 148 weeks) and Safety Follow-up (Up to 152.3 Weeks)

  8. Maintenance Phase: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs According to National Cancer Institute-Common Terminology Criteria for Adverse Events Version 4.03 (NCI-CTCAE v4.03)

    Adverse event (AE) was defined as any untoward medical occurrence in a participant, which does not necessarily have causal relationship with treatment. A serious AE was defined as an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged in participant hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. The term TEAE is defined as AEs starting or worsening after the first intake of the study drug. TEAEs included both serious TEAEs and non-serious TEAEs. Number of participants with TEAEs and serious TEAEs were reported.

    Time frame: From randomization into maintenance phase up to 1276 days

  9. Maintenance Phase: Number of Participants With Grade Change From Baseline to Worst On-Treatment Grade 4 Hematology Values

    Blood samples were collected for the analysis of following hematology parameters: lymphocyte count, neutrophil count, white blood cells, platelet count, lipase, serum amylase, creatinine phosphokinase and creatinine. The hematology parameters were graded according to National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. An increase is defined as an increase in CTCAE grade relative to Baseline grade. Data for worst-case (Grade 4) post Baseline is presented. Only those participants with increase to grade 4 have been presented.

    Time frame: From baseline up to 1276 days

  10. Maintenance Phase: Number of Participants With Potentially Clinically Significant Abnormalities in Vital Signs

    Vital signs assessment included Systolic blood pressure (SBP), Diastolic blood pressure (DBP) and Pulse Rate (PR). Number of Participants with any potentially clinically significant abnormalities in vital signs were reported. Clinical significance was determined by the investigator.

    Time frame: From randomization into maintenance phase up to 1276 days

  11. Maintenance Phase: Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Abnormalities

    ECG parameters included heart rate, pulse rate intervals, QRS interval, QT interval corrected based on Fridericia's formula (QTcF) intervals and QTcB intervals. Clinical significance was determined by the investigator. Number of participants with potentially clinically significant ECG abnormalities were reported.

    Time frame: From randomization into maintenance phase up to 1276 days

  12. Maintenance Phase: Number of Participants With Shift in Eastern Cooperative Oncology Group (ECOG) Performance Status Score to 1 or Higher Than 1

    ECOG PS score is widely used by doctors and researchers to assess how a participants' disease is progressing, and is used to assess how the disease affects the daily living abilities of the participant, and determine appropriate treatment and prognosis. The score ranges from Grade 0 to Grade 5, where Grade 0 = Fully active, able to carry on all pre-disease performance without restriction, Grade 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature (like light house work, office work), Grade 2 = Ambulatory and capable of all self-care but unable to carry out any work activities, Grade 3 = Capable of only limited self-care, confined to bed or chair more than 50% of waking hours and Grade 4 = Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair, Grade 5 = Death. Number of participants with shift in ECOG PS Score to 1 or Higher Than 1 were reported.

    Time frame: From randomization into maintenance phase up to 1276 days

07

Results

Posted Nov 4, 2021

Participant flow

Participant flow — Overall Study
MilestoneChemotherapy + Best Supportive Care (BSC)Avelumab
Started250249
Safety-maintenance analysis set238243
Completed250249
Not completed00

Outcome measures

PrimaryOverall Survival (OS)

Overall Survival was defined as the time from randomization to the date of death due to any cause. For participants who were still alive at the time of data analysis or who were lost to follow-up, OS time was censored at the date of last contact. OS was measured using Kaplan-Meier (KM) estimates.

Time frame:
From randomization into maintenance phase up to 1276 days
Reported as:
Median · months
Overall Survival (OS)
monthsChemotherapy + Best Supportive Care (BSC)Avelumab
Overall Survival (OS)10.9 (9.6 to 12.4)10.4 (9.1 to 12.0)
Statistical analysis
  • Chemotherapy + Best Supportive Care (BSC) vs Avelumab · Log Rank · p = 0.1779 · Hazard ratio (hr): 0.91 · 95% CI 0.74 to 1.11The treatment arms were compared using a stratified, 1-sided, log rank Test. The stratification factor was region (Asia versus non Asia).
SecondaryProgression Free Survival (PFS) by Independent Review Committee (IRC)

The PFS time was defined as the time from date of randomization until date of the first documentation of progressive disease (PD) or death due to any cause (whichever occurs first). PFS was assessed as per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) as per IRC. PD was defined as at least a 20 percent (%) increase in the sum of longest diameter (SLD), taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. PFS was measured using Kaplan-Meier (KM) estimates.

Time frame:
From randomization into maintenance phase up to 1276 days
Reported as:
Median · months
Progression Free Survival (PFS) by Independent Review Committee (IRC)
monthsChemotherapy + Best Supportive Care (BSC)Avelumab
Progression Free Survival (PFS) by Independent Review Committee (IRC)4.4 (4.0 to 5.5)3.2 (2.8 to 4.1)
Statistical analysis
  • Chemotherapy + Best Supportive Care (BSC) vs Avelumab · Hazard ratio (hr): 1.04 · 95% CI 0.85 to 1.28
SecondaryBest Overall Response (BOR) by Investigator Assessment

BOR was determined by RECIST v1.1 per Investigator assessment and defined as best-confirmed response of any of following: complete response (CR), partial response (PR), stable disease (SD) and PD recorded from date of randomization until disease progression or recurrence. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in SLD of all lesions. SD: Neither sufficient increase to qualify for PD nor sufficient shrinkage to qualify for PR. PD is defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or appearance of 1 or more new lesions. PR or CR confirmed at a subsequent tumor assessment, not sooner than 5 weeks after initial documentation or at an assessment later than the next assessment after the initial documentation of PR or CR. SD confirmed at least 6 weeks after randomization. Confirmed PD equal to progression \<=2 weeks after date of randomization.

Time frame:
From randomization into maintenance phase up to 1276 days
Reported as:
Count of participants · Participants
Best Overall Response (BOR) by Investigator Assessment
ParticipantsChemotherapy + Best Supportive Care (BSC)Avelumab
Complete response58
Partial response3125
Stable disease11792
Noncomplete response/non progressive disease1110
Progressive disease5885
Non evaluable2829
SecondaryObjective Response Rate (ORR) by Investigator Assessment

The ORR defined as the percentage of all randomized participants with a confirmed best overall response (BOR) of partial response (PR),or complete response (CR) according to RECIST v1.1 and as per Investigator assessment. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in sum of longest diameter (SLD) of all lesions.

Time frame:
From randomization into maintenance phase up to 1276 days
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) by Investigator Assessment
percentage of participantsChemotherapy + Best Supportive Care (BSC)Avelumab
Objective Response Rate (ORR) by Investigator Assessment14.4 (10.3 to 19.4)13.3 (9.3 to 18.1)
Statistical analysis
  • Chemotherapy + Best Supportive Care (BSC) vs Avelumab · Odds ratio (or): 0.91 · 95% CI 0.55 to 1.51
SecondaryChange From Baseline in European Quality of Life 5-dimensions (EQ-5D-5L) Health Outcome Questionnaire Through Composite Index Score up to Safety Follow-up (Up to 152.3 Weeks)

EQ-5D-5L is comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive overall composite health state index score, with scores ranging from -0.594 to 1. A higher score indicates better health state.

Time frame:
Baseline, Week 3/4, Week 7, Week 13, Week 19, Week 25, Week 31, Week 37, Week 43, Week 49, Week 55, Week 61, Week 67, End of Treatment ( EOT up to 148 weeks) and Safety Follow-up (Up to 152.3 Weeks)
Reported as:
Mean · Units on Scale
Change From Baseline in European Quality of Life 5-dimensions (EQ-5D-5L) Health Outcome Questionnaire Through Composite Index Score up to Safety Follow-up (Up to 152.3 Weeks)
Units on ScaleChemotherapy + Best Supportive Care (BSC)Avelumab
Week 3/4-0.002 ± 0.12420.004 ± 0.1610
Week 7-0.032 ± 0.1644-0.009 ± 0.1588
Week 13-0.053 ± 0.1733-0.017 ± 0.1599
Week 19-0.039 ± 0.1934-0.011 ± 0.1556
Week 25-0.049 ± 0.17970.014 ± 0.1518
Week 31-0.023 ± 0.16190.013 ± 0.1665
Week 37-0.035 ± 0.15050.013 ± 0.2234
Week 43-0.046 ± 0.13600.058 ± 0.1990
Week 49-0.100 ± 0.17960.026 ± 0.1936
Week 55-0.164 ± 0.20560.028 ± 0.2067
Week 61-0.091 ± 0.22290.031 ± 0.1364
Week 67-0.076 ± 0.23470.039 ± 0.1954
End Of Treatment-0.125 ± 0.2432-0.138 ± 0.2461
Safety Follow-Up-0.062 ± 0.2391-0.099 ± 0.1942
SecondaryChange From Baseline in European Quality of Life 5-dimensions Health Outcome Questionnaire Through Visual Analogue Scale up to Safety Follow-up (Up to 152.3 Weeks)

EQ-5D-5L is comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive overall score using a visual analog scale (VAS) that ranged from 0 to 100 millimeter (mm), where 0 is the worst health you can imagine and 100 is the best health you can imagine.

Time frame:
Baseline, Week 3/4, Week 7, Week 13, Week 19, Week 25, Week 31, Week 37, Week 43, Week 49, Week 55, Week 61, Week 67, End of Treatment ( EOT up to 148 weeks) and Safety Follow-up (Up to 152.3 Weeks)
Reported as:
Mean · Millimeter
Change From Baseline in European Quality of Life 5-dimensions Health Outcome Questionnaire Through Visual Analogue Scale up to Safety Follow-up (Up to 152.3 Weeks)
MillimeterChemotherapy + Best Supportive Care (BSC)Avelumab
Week 3/40.9 ± 13.940.6 ± 13.11
Week 7-0.5 ± 13.59-2.1 ± 14.09
Week 13-3.2 ± 12.83-0.7 ± 13.41
Week 19-3.5 ± 16.39-0.1 ± 14.93
Week 25-4.5 ± 15.66-1.4 ± 15.76
Week 31-2.3 ± 13.141.4 ± 17.61
Week 37-1.7 ± 11.780.9 ± 20.39
Week 43-4.4 ± 11.923.2 ± 15.34
Week 49-2.9 ± 8.952.1 ± 13.04
Week 55-9.4 ± 16.323.4 ± 16.52
Week 61-6.4 ± 18.093.5 ± 16.15
Week 67-7.3 ± 17.104.9 ± 17.31
End Of Treatment-12.2 ± 22.39-10.3 ± 20.84
Safety Follow-Up-8.0 ± 19.24-9.6 ± 20.30
SecondaryChange From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) Global Health Status Scale Score up to Safety Follow-up (Up to 152.3 Weeks)

European Organization for the Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life (QoL) in cancer participants. It consisted of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, role, cognitive, emotional, social), and 9 symptom scales/items (Fatigue, nausea and vomiting, pain, dyspnoea, sleep disturbance, appetite loss, constipation, diarrhea, financial impact. The EORTC QLQ-C30 GHS/QoL score ranges from 0 to 100; High score indicates better GHS/QoL. Score 0 represents: very poor physical condition and QoL. Score 100 represents: excellent overall physical condition and QoL.

Time frame:
Baseline, Week 3/4, Week 7, Week 13, Week 19, Week 25, Week 31, Week 37, Week 43, Week 49, Week 55, Week 61, Week 67, End of Treatment ( EOT up to 148 weeks) and Safety Follow-up (Up to 152.3 Weeks)
Reported as:
Mean · units on a scale
Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) Global Health Status Scale Score up to Safety Follow-up (Up to 152.3 Weeks)
units on a scaleChemotherapy + Best Supportive Care (BSC)Avelumab
Week 3/41.30 ± 15.4860.85 ± 15.021
Week 7-1.44 ± 14.905-1.01 ± 16.967
Week 13-2.50 ± 15.4240.24 ± 17.637
Week 19-5.85 ± 18.3631.37 ± 18.611
Week 25-4.43 ± 15.4070.41 ± 16.204
Week 31-3.09 ± 19.9021.85 ± 16.938
Week 37-1.39 ± 22.1861.77 ± 19.293
Week 43-1.19 ± 12.1673.33 ± 18.518
Week 491.52 ± 9.7314.01 ± 15.907
Week 550.00 ± 11.7854.00 ± 15.426
Week 61-5.00 ± 13.9442.38 ± 15.622
Week 670.00 ± 9.1294.90 ± 18.413
End Of Treatment-11.54 ± 23.460-11.67 ± 21.409
Safety Follow-Up-7.51 ± 19.475-9.29 ± 24.881
SecondaryChange From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Stomach Cancer Specific (EORTC QLQ-STO22 ) Questionnaire Scores up to Safety Follow-up (Up to 152.3 Weeks)

European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Stomach Cancer Specific (EORTC QLQ-STO22 ) supplements the EORTC QLQ-C30 to assess symptoms and treatment-related side effects commonly reported in participants. There are 22 questions which comprise 5 scales (dysphagia, pain, reflux symptom, dietary restrictions, and anxiety) and 4 single items (dry mouth, hair loss, taste, body image). Most questions use 4-point scale (1 'Not at all' to 4 'Very much'; 1 question was a yes or no answer). A linear transformation was used to standardize all scores and single-items to a scale of 0 to 100; higher score=better level of functioning or greater degree of symptoms.

Time frame:
Baseline, Week 3/4, Week 7, Week 13, Week 19, Week 25, Week 31, Week 37, Week 43, Week 49, Week 55, Week 61, Week 67, End of Treatment ( EOT up to 148 weeks) and Safety Follow-up (Up to 152.3 Weeks)
Reported as:
Mean · units on a scale
Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Stomach Cancer Specific (EORTC QLQ-STO22 ) Questionnaire Scores up to Safety Follow-up (Up to 152.3 Weeks)
units on a scaleChemotherapy + Best Supportive Care (BSC)Avelumab
Dysphagia: Week 3/40.76 ± 13.3710.60 ± 15.227
Dysphagia Week 72.84 ± 15.2581.34 ± 13.453
Dysphagia Week 131.60 ± 14.0900.65 ± 12.781
Dysphagia Week 19-0.58 ± 15.7721.52 ± 14.307
Dysphagia Week 25-1.39 ± 10.4651.69 ± 14.852
Dysphagia Week 310.82 ± 14.7554.39 ± 20.877
Dysphagia Week 37-7.19 ± 17.977-0.67 ± 14.683
Dysphagia Week 43-4.76 ± 14.265-2.59 ± 13.270
Dysphagia Week 49-3.03 ± 8.7361.23 ± 13.195
Dysphagia Week 550.00 ± 13.6080.89 ± 13.194
Dysphagia Week 610.00 ± 15.7131.06 ± 12.123
Dysphagia Week 67-1.85 ± 10.9241.31 ± 17.516
Dysphagia End Of Treatment7.27 ± 25.1348.21 ± 22.633
Dysphagia Safety Follow-Up9.39 ± 21.4677.25 ± 19.417
Pain Week 3/41.51 ± 13.013-0.04 ± 13.465
Pain Week 72.53 ± 15.3512.60 ± 15.210
Pain Week 132.96 ± 14.5850.16 ± 13.523
Pain Week 193.22 ± 14.152-0.51 ± 14.088
Pain Week 25-1.56 ± 13.789-1.55 ± 17.540
Pain Week 314.01 ± 19.1110.97 ± 18.564
Pain Week 37-4.90 ± 19.777-1.26 ± 12.346
Pain Week 431.79 ± 18.251-1.94 ± 14.129
Pain Week 491.52 ± 5.025-0.62 ± 12.853
Pain Week 550.00 ± 19.543-1.00 ± 10.012
Pain Week 613.33 ± 9.501-1.59 ± 13.596
Pain Week 670.00 ± 12.910-0.49 ± 15.721
Pain End Of Treatment9.25 ± 20.8539.45 ± 22.960
Pain Safety Follow-Up8.22 ± 18.01110.99 ± 20.931
Reflux Week 3/41.04 ± 14.1970.12 ± 13.571
Reflux Week 70.31 ± 14.6950.50 ± 17.807
Reflux Week 130.99 ± 14.098-1.09 ± 15.753
Reflux Week 191.75 ± 17.032-1.68 ± 15.377
Reflux Week 250.69 ± 14.6481.69 ± 19.770
Reflux Week 31-2.06 ± 14.791-1.29 ± 18.339
Reflux Week 37-6.54 ± 18.864-4.38 ± 17.773
Reflux Week 43-3.17 ± 15.364-5.56 ± 16.699
Reflux Week 491.01 ± 9.236-2.06 ± 16.317
Reflux Week 552.22 ± 4.969-3.56 ± 19.699
Reflux Week 616.67 ± 9.938-6.35 ± 12.944
Reflux Week 677.41 ± 13.4560.00 ± 19.245
Reflux End of Treatment3.43 ± 19.5294.73 ± 20.455
Reflux Safety Follow-up1.56 ± 20.2542.90 ± 19.212
Eating Restrictions Week 3/40.73 ± 16.2790.13 ± 15.438
Eating Restrictions Week 70.98 ± 16.123-0.27 ± 15.516
Eating Restrictions Week 131.02 ± 14.2340.00 ± 14.023
Eating Restrictions Week 19-2.34 ± 16.648-0.63 ± 11.993
Eating Restrictions Week 25-2.08 ± 18.208-1.55 ± 15.434
Eating Restrictions Week 31-2.47 ± 15.8140.39 ± 14.880
Eating Restrictions Week 37-8.82 ± 21.943-3.28 ± 15.014
Eating Restrictions Week 43-4.76 ± 18.115-3.89 ± 13.443
Eating Restrictions Week 490.76 ± 11.459-5.25 ± 12.043
Eating Restrictions Week 553.33 ± 15.138-6.00 ± 12.620
Eating Restrictions Week 610.00 ± 15.590-5.56 ± 12.999
Eating Restrictions Week 671.39 ± 13.351-2.45 ± 19.712
Eating Restrictions EOT8.27 ± 20.89810.01 ± 22.055
Eating Restrictions Safety Follow-up7.04 ± 24.05511.59 ± 25.050
Anxiety Week 3/4-0.28 ± 16.150-4.06 ± 18.030
Anxiety Week 7-1.30 ± 16.947-1.20 ± 20.580
Anxiety Week 13-0.86 ± 20.685-2.83 ± 16.300
Anxiety Week 19-1.56 ± 21.561-1.68 ± 19.220
Anxiety Week 25-2.78 ± 23.780-1.69 ± 14.562
Anxiety Week 314.12 ± 23.700-0.52 ± 24.119
Anxiety Week 37-3.92 ± 20.765-1.01 ± 27.409
Anxiety Week 43-3.97 ± 22.480-1.11 ± 24.474
Anxiety Week 490.00 ± 12.172-6.17 ± 17.792
Anxiety Week 552.22 ± 9.296-4.00 ± 20.000
Anxiety Week 61-4.44 ± 12.669-4.76 ± 24.488
Anxiety Week 679.26 ± 16.355-1.96 ± 24.918
Anxiety End of Treatment4.58 ± 21.8685.89 ± 23.939
Anxiety Safety Follow-Up5.48 ± 24.1164.99 ± 26.234
SecondaryMaintenance Phase: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs According to National Cancer Institute-Common Terminology Criteria for Adverse Events Version 4.03 (NCI-CTCAE v4.03)

Adverse event (AE) was defined as any untoward medical occurrence in a participant, which does not necessarily have causal relationship with treatment. A serious AE was defined as an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged in participant hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. The term TEAE is defined as AEs starting or worsening after the first intake of the study drug. TEAEs included both serious TEAEs and non-serious TEAEs. Number of participants with TEAEs and serious TEAEs were reported.

Time frame:
From randomization into maintenance phase up to 1276 days
Reported as:
Count of participants · Participants
Maintenance Phase: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs According to National Cancer Institute-Common Terminology Criteria for Adverse Events Version 4.03 (NCI-CTCAE v4.03)
ParticipantsChemotherapy + Best Supportive Care (BSC)Avelumab
Any TEAEs214223
Any Serious TEAE7589
SecondaryMaintenance Phase: Number of Participants With Grade Change From Baseline to Worst On-Treatment Grade 4 Hematology Values

Blood samples were collected for the analysis of following hematology parameters: lymphocyte count, neutrophil count, white blood cells, platelet count, lipase, serum amylase, creatinine phosphokinase and creatinine. The hematology parameters were graded according to National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. An increase is defined as an increase in CTCAE grade relative to Baseline grade. Data for worst-case (Grade 4) post Baseline is presented. Only those participants with increase to grade 4 have been presented.

Time frame:
From baseline up to 1276 days
Reported as:
Count of participants · Participants
Maintenance Phase: Number of Participants With Grade Change From Baseline to Worst On-Treatment Grade 4 Hematology Values
ParticipantsChemotherapy + Best Supportive Care (BSC)Avelumab
lymphocyte count decreased01
neutrophil count decreased61
white blood cells decreased20
platelet count decreased10
lipase increased68
serum amylase increased32
creatinine phosphokinase increased02
creatinine increased01
SecondaryMaintenance Phase: Number of Participants With Potentially Clinically Significant Abnormalities in Vital Signs

Vital signs assessment included Systolic blood pressure (SBP), Diastolic blood pressure (DBP) and Pulse Rate (PR). Number of Participants with any potentially clinically significant abnormalities in vital signs were reported. Clinical significance was determined by the investigator.

Time frame:
From randomization into maintenance phase up to 1276 days
Reported as:
Count of participants · Participants
Maintenance Phase: Number of Participants With Potentially Clinically Significant Abnormalities in Vital Signs
ParticipantsChemotherapy + Best Supportive Care (BSC)Avelumab
Increased in Systolic blood pressure5762
Decreased in Systolic blood pressure4369
Increased in Diastolic blood pressure1424
Decreased in Diastolic blood pressure2126
Increased in pulse rate4648
Decreased in pulse rate3230
SecondaryMaintenance Phase: Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Abnormalities

ECG parameters included heart rate, pulse rate intervals, QRS interval, QT interval corrected based on Fridericia's formula (QTcF) intervals and QTcB intervals. Clinical significance was determined by the investigator. Number of participants with potentially clinically significant ECG abnormalities were reported.

Time frame:
From randomization into maintenance phase up to 1276 days
Reported as:
Count of participants · Participants
Maintenance Phase: Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Abnormalities
ParticipantsChemotherapy + Best Supportive Care (BSC)Avelumab
Decreased heart rate01
Increased heart rate22
Increased Pulse Rate interval13
Increased QRS interval58
QTcF interval greater than (>)450milisecond (ms)less than or equal to(<=)480ms99
QTcF interval: > 480 ms <= 500 ms23
QTcF interval: > 500 ms31
QTcB Interval: > 450 msec <= 480 msec1918
QTcB Interval: > 480 msec <= 500 msec22
QTcB Interval: > 500 msec53
SecondaryMaintenance Phase: Number of Participants With Shift in Eastern Cooperative Oncology Group (ECOG) Performance Status Score to 1 or Higher Than 1

ECOG PS score is widely used by doctors and researchers to assess how a participants' disease is progressing, and is used to assess how the disease affects the daily living abilities of the participant, and determine appropriate treatment and prognosis. The score ranges from Grade 0 to Grade 5, where Grade 0 = Fully active, able to carry on all pre-disease performance without restriction, Grade 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature (like light house work, office work), Grade 2 = Ambulatory and capable of all self-care but unable to carry out any work activities, Grade 3 = Capable of only limited self-care, confined to bed or chair more than 50% of waking hours and Grade 4 = Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair, Grade 5 = Death. Number of participants with shift in ECOG PS Score to 1 or Higher Than 1 were reported.

Time frame:
From randomization into maintenance phase up to 1276 days
Reported as:
Count of participants · Participants
Maintenance Phase: Number of Participants With Shift in Eastern Cooperative Oncology Group (ECOG) Performance Status Score to 1 or Higher Than 1
ParticipantsChemotherapy + Best Supportive Care (BSC)Avelumab
Maintenance Phase: Number of Participants With Shift in Eastern Cooperative Oncology Group (ECOG) Performance Status Score to 1 or Higher Than 1140144

Adverse events

Collected over From randomization into maintenance phase up to 1276 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Chemotherapy + Best Supportive Care (BSC)13/238 (5.5%)75/238 (31.5%)203/238 (85.3%)
Avelumab16/243 (6.6%)89/243 (36.6%)191/243 (78.6%)
Most frequent serious events
Showing 10 of 125
Most frequent serious events
EventChemotherapy + Best Supportive Care (BSC)Avelumab
Disease progressionGeneral disorders6/23814/243
DysphagiaGastrointestinal disorders2/2386/243
VomitingGastrointestinal disorders4/2384/243
Obstruction gastricGastrointestinal disorders4/2383/243
Gastric haemorrhageGastrointestinal disorders4/2380/243
Decreased appetiteMetabolism and nutrition disorders4/2384/243
Abdominal painGastrointestinal disorders2/2384/243
PyrexiaGeneral disorders2/2384/243
PneumonitisRespiratory, thoracic and mediastinal disorders1/2384/243
AscitesGastrointestinal disorders3/2383/243
Most frequent other events
Showing 10 of 43
Most frequent other events
EventChemotherapy + Best Supportive Care (BSC)Avelumab
NauseaGastrointestinal disorders52/23841/243
AnaemiaBlood and lymphatic system disorders48/23835/243
Peripheral sensory neuropathyNervous system disorders42/23814/243
Decreased appetiteMetabolism and nutrition disorders42/23826/243
DiarrhoeaGastrointestinal disorders39/23827/243
NeutropeniaBlood and lymphatic system disorders36/23812/243
Neutrophil count decreasedInvestigations35/2384/243
FatigueGeneral disorders29/23835/243
Platelet count decreasedInvestigations34/2386/243
ThrombocytopeniaBlood and lymphatic system disorders34/2388/243

Baseline characteristics

Full analysis set included all randomized participants included in treatment arm to which they were randomized.

Age, Continuous
Age, Continuous(Years)Chemotherapy + Best Supportive Care (BSC)AvelumabTotal
Mean60.6 ± 11.7060.7 ± 11.0360.7 ± 11.36
Sex: Female, Male
Sex: Female, Male(Participants)Chemotherapy + Best Supportive Care (BSC)AvelumabTotal
Female8385168
Male167164331
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Chemotherapy + Best Supportive Care (BSC)AvelumabTotal
Hispanic or Latino151934
Not Hispanic or Latino213220433
Unknown or Not Reported221032
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Chemotherapy + Best Supportive Care (BSC)AvelumabTotal
White161171332
Black or African American224
Asian5961120
American Indian or Alaska Native202
Native Hawaiian or other Pacific Islander000
Not collected at this site221234
Other336
Missing101
08

Study locations

200 sites
  • Comprehensive Blood & Cancer Center
    Bakersfield, California 93309, United States
  • Virginia Crosson Cancer Center
    Fullerton, California 92835, United States
  • UCLA Medical Center
    Los Angeles, California 90095, United States
  • Desert Hematology Oncology Medical Group, Inc.
    Rancho Mirage, California 92262, United States
  • Sansum Clinic
    Santa Barbara, California 93105, United States
  • Trio - Central Coast Medical Oncology Corporation
    Santa Maria, California 93454, United States
  • Norwalk Hospital
    Norwalk, Connecticut 6856, United States
  • UF Health Cancer Center Orlando
    Orlando, Florida 32806, United States
  • Memorial West Cancer Institute
    Pembroke Pines, Florida 33028, United States
  • University of South Florida - Parent
    Tampa, Florida 33606, United States
  • Oncology Specialists, S.C.
    Park Ridge, Illinois 60068, United States
  • Franciscan St. Francis Health Cancer Center
    Indianapolis, Indiana 46237, United States
  • Cedar Rapids Oncology Project
    Cedar Rapids, Iowa 52403, United States
  • Cotton-O'Neil Clinical Research Center, Hematology and Oncology
    Topeka, Kansas 66604, United States
  • University of Kansas Medical Center Research Institute, Inc.
    Westwood, Kansas 66205, United States
  • Virginia Piper Cancer Institute
    Minneapolis, Minnesota 55407, United States
  • Nevada Cancer Research Foundation
    Las Vegas, Nevada 89106, United States
  • Mount Sinai - PRIME
    Jamaica, New York 11432, United States
  • Clinical Research Alliance, Inc
    New York, New York 10021, United States
  • University of Rochester
    Rochester, New York 14642, United States
  • UC Health Clinical Trials Office
    Cincinnati, Ohio 45206, United States
  • TriHealth Hatton Institute
    Cincinnati, Ohio 45220, United States
  • Mid Ohio Oncology Hematology, DBA The Mark H. Zangmeister Center
    Columbus, Ohio 43219, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • St. Luke's Hospital
    Bethlehem, Pennsylvania 18015, United States
  • Thomas Jefferson University Hospital
    Philadelphia, Pennsylvania 19107, United States
  • Rhode Island Hospital
    Providence, Rhode Island 02903, United States
  • Greenville Hospital System University Medical Center (ITOR)
    Greenville, South Carolina 29605, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390-9179, United States
  • Oncology Consultants, P.A.
    Houston, Texas 77024, United States
  • University of Texas Health Science Center at San Antonio
    San Antonio, Texas 78229, United States
  • Baylor Scott & White Health
    Temple, Texas 76508, United States
  • University of Washington - Seattle Cancer Care Alliance
    East Seattle, Washington 98109, United States
  • Northwest Medical Specialties, PLLC
    Tacoma, Washington 98405, United States
  • Wenatchee Valley Hospital & Clinics
    Wenatchee, Washington 98801, United States
  • St George Hospital
    Kogarah, New South Wales 2217, Australia
  • Royal North Shore Hospital
    St Leonards, New South Wales 2065, Australia
  • Greenslopes Private Hospital
    Greenslopes, Queensland 4120, Australia
  • Royal Brisbane and Women's Hospital
    Herston, Queensland 4006, Australia
  • Flinders Medical Centre
    Bedford Park, South Australia 5042, Australia
  • Lyell McEwin Hospital
    Elizabeth Vale, South Australia 5112, Australia
  • Royal Hobart Hospital
    Hobart, Tasmania 7000, Australia
  • Ballarat Base Hospital
    Ballarat, Victoria 3350, Australia
  • Bendigo Hospital
    Bendigo, Victoria 3550, Australia
  • Monash Medical Centre Clayton
    Bentleigh, Victoria 8120, Australia
  • Box Hill Hospital
    Box Hill, Victoria 3128, Australia
  • Royal Melbourne Hospital
    Parkville, Victoria 3050, Australia
  • Border Medical Oncology
    Wodonga, Victoria 3690, Australia
  • Fiona Stanley Hospital
    Murdoch, Western Australia 6150, Australia
  • NOB - Núcleo de Oncologia da Bahia
    Salvador, Bahia 40170-110, Brazil
  • Hospital São Lucas da PUCRS
    Ijuí, Rio Grande Do Sul 98700-000, Brazil
  • Hospital Bruno Born
    Lajeado, Rio Grande Do Sul 95900-000, Brazil
  • Oncosinos - Clínica de Oncologia - Hospital Regina
    Novo Hamburgo, Rio Grande Do Sul 93510-250, Brazil
  • Hospital de Clínicas de Porto Alegre
    Porto Alegre, Rio Grande Do Sul 90035-903, Brazil
  • Hospital São Lucas da PUCRS
    Porto Alegre, Rio Grande Do Sul 90610-000, Brazil
  • Hospital de Câncer de Barretos-Fundação Pio XII
    Barretos, Sao Paulo 14784-400, Brazil
  • IMV - Instituto De Medicina Vascular Hospital Mae de Deus
    Porto Alegre, Sao Paulo 90110-270, Brazil
  • CEPHO - Centro de Estudos e Pesquisas em Hematologia e Oncologia
    Santo Andre, Sao Paulo 09060-650, Brazil
  • Fundação Faculdade Regional de Medicina de São José do Rio Preto
    São José do Rio Preto, Sao Paulo 15090-000, Brazil
  • ICESP - Instituto do Câncer do Estado de São Paulo Octavio Frias de Oliveira
    São Paulo, Sao Paulo 01246-000, Brazil
  • Hospital Infanta Cristina
    Badajoz, 06080, Brazil
  • Queen Elizabeth II Health Sciences Centre
    Halifax, Nova Scotia B3H 2Y9, Canada
  • The Royal Victoria Hospital
    Barrie, Ontario L4M 6M2, Canada
  • Humber River Hospital
    Toronto, Ontario M3M 0B2, Canada
  • Mount Sinai Hospital
    Toronto, Ontario M5G 1X5, Canada
  • Cité de la Santé de Laval
    Laval, Quebec H7M 3L9, Canada
  • McGill University - Dept. Oncology Clinical Research Program
    Montréal, Quebec H2W 1S6, Canada
  • Centre Antoine Lacassagne
    Nice cedex 02, Alpes Maritimes 06189, France
  • Hôpital de la Timone
    Marseille cedex 5, Bouches Du Rhone 13385, France
  • Hôpital Morvan
    Brest, Brittany 29200, France
  • Centre Georges François Leclerc
    Dijon cedex, Côte-d'Or 21079, France
  • CHU Besancon - Hopital Jean Minjoz
    Besancon, Doubs 25030, France
  • CHU Bordeaux
    Bordeaux Cedex, Gironde 33076, France
  • CHU de Toulouse - Hôpital Rangueil
    Toulouse Cedex 9, Haute Garonne 31059, France
  • CRLCC Eugene Marquis
    Rennes cedex, Ille Et Vilaine 35042, France
  • CHU Tours - Hôpital Trousseau
    Chambray les Tours, Indre Et Loire 37170, France
  • ICO - Site René Gauducheau
    Angers Cedex 9, Maine Et Loire 49933, France
  • Hôpital Cochin
    Paris cedex 14, Paris 75679, France
  • Hôpital Européen Georges Pompidou
    Paris Cedex 15, Paris 75015, France
  • CHU Clermont Ferrand
    Clermont Ferrand cedex 1, Puy De Dome 63003, France
  • Clinique Victor Hugo - Centre Jean Bernard
    Le Mans Cedex 02, Sarthe 72015, France
  • Klinikum Esslingen GmbH
    Esslingen A. N., Baden Wuerttemberg 73730, Germany
  • SLK-Kliniken Heilbronn GmbH
    Heilbronn, Baden Wuerttemberg 74078, Germany
  • Klinikum Bogenhausen
    Muenchen, Bayern 81925, Germany
  • Leopoldina Krankenhaus Schweinfurt
    Schweinfurt, Bayern 97422, Germany
  • Krankenhaus Nordwest GmbH
    Frankfurt, Hessen 60488, Germany
  • Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz
    Mainz, Rheinland Pfalz 55131, Germany
  • Onkologische Schwerpunktpraxis Eppendorf
    Hamburg, 20249, Germany
  • Marienkrankenhaus Hamburg
    Hamburg, 22087, Germany
  • Pecsi Tudomanyegyetem
    Pecs, Baranya 7624, Hungary
  • Petz Aladar Megyei Oktato Korhaz
    Gyor, Győr-Moson-Sopron 9024, Hungary
  • Debreceni Egyetem Klinikai Kozpont
    Debrecen, Hajdú-Bihar 4032, Hungary
  • Magyar Honvedseg Egeszsegugyi
    Budapest, 1062, Hungary
  • SzSzB Megyei Korhazak es Egyetemi Oktatokorhaz
    Nyiregyhaza, 4400, Hungary
  • Tolna Megyei Balassa Janos Korhaz
    Szekszard, 7100, Hungary
  • Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet
    Szolnok, 5000, Hungary
  • Zala Megyei Szent Rafael Korhaz
    Zalaegerszeg, 8900, Hungary
  • Presidio Ospedaliero Garibaldi Nesima
    Catania, 95100, Italy
  • Azienda Socio Sanitaria Territoriale di Cremona (Istituti Ospitalieri di Cremona)
    Cremona, 26100, Italy
  • Azienda Ospedaliera Universitaria Careggi
    Firenze, 50141, Italy

Showing the first 100 of 200 sites across 17 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Chang X, Ge X, Zhang Y, Xue X. The current management and biomarkers of immunotherapy in advanced gastric cancer. Medicine (Baltimore). 2022 May 27;101(21):e29304. doi: 10.1097/MD.0000000000029304. PubMed 35623069 ↗
  • Moehler M, Dvorkin M, Boku N, Ozguroglu M, Ryu MH, Muntean AS, Lonardi S, Nechaeva M, Bragagnoli AC, Coskun HS, Cubillo Gracian A, Takano T, Wong R, Safran H, Vaccaro GM, Wainberg ZA, Silver MR, Xiong H, Hong J, Taieb J, Bang YJ. Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100. J Clin Oncol. 2021 Mar 20;39(9):966-977. doi: 10.1200/JCO.20.00892. Epub 2020 Nov 16. PubMed 33197226 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2015 to primary completion in Sep 2019, 44 months.

Results were first posted in Nov 2021, 2 years 1 month after primary completion. A results delay was requested in Oct 2019.

Of 83 industry-sponsored phase 3 interventional studies under Neoplasm Metastasis, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 57. This study's 44 months is close to that.

Counting every sponsor, half of 138 studies reached it within 49 months; a quarter within 36 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2015
First posted
Dec 9, 2015
StartActual
Dec 24, 2015
Primary completionActual
Sep 13, 2019
CompletionActual
Jun 3, 2021
Results delay requested
Oct 10, 2019
Results first posted
Nov 4, 2021
Last update
Jun 9, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02625610
Responsible party
Sponsor
First posted
Dec 9, 2015
Start date
Dec 24, 2015
Primary completion
Sep 13, 2019
Completion
Jun 3, 2021
Results posted
Nov 4, 2021
Last update
Jun 9, 2022

Study contacts

Medical Responsible
study director · EMD Serono Research & Development Institute, Inc. a business of Merck KGaA, Darmstadt, Germany

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Avelumab · Oxaliplatin · Fluorouracil · Leucovorin · Capecitabine

Start the discussion